"Fort de plus de 5 500 collaborateurs et médecins, le Groupe Jolimont fédère un réseau d’institutions actives dans le Brabant Wallon et le Hainaut. Celles-ci ont pour but d’établir entre elles diverses formes de solidarité, de partager des compétences, des valeurs humaines, des intérêts scientifiques, de renforcer leur complémentarité en étant actives dans le domaine des soins hospitaliers et ambulatoires et dans les domaines de l’accueil des enfants, des personnes âgées et de toute personne en difficulté de vie. Le Groupe Jolimont est le premier groupe de santé wallon."

During the past decade, Hopital de Jolimont conducted 13 clinical trials. In the 10-year time frame, 13 clinical trials started and 5 clinical trials were completed, i.e. on average, 38.5% percent of trials that started reached the finish line to date. In the past 5 years, 6 clinical trials started and 4 clinical trials were completed. i.e. 66.7% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Hopital de Jolimont" #1 sponsor was "European Organisation for Research and Treatment of Cancer - EORTC" with 3 trials, followed by "Amgen" with 2 trials sponsored, "Eli Lilly and Company" with 2 trials sponsored, "Janssen Research & Development, LLC" with 2 trials sponsored and "Pfizer" with 2 trials sponsored. Other sponsors include 7 different institutions and companies that sponsored additional 17 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Hopital de Jolimont" #1 collaborator was "Borstkanker Onderzoek Groep" with 2 trials as a collaborator, "Breast International Group" with 2 trials as a collaborator, "Cancer Trials Ireland" with 2 trials as a collaborator, "Hoffmann-La Roche" with 2 trials as a collaborator and "Belgian Hematological Society" with 1 trials as a collaborator. Other collaborators include 13 different institutions and companies that were collaborators in the rest 23 trials.

According to Clinical.Site data, the most researched conditions in "Hopital de Jolimont" are "Breast Cancer" (3 trials), "Multiple Myeloma" (2 trials), "Acute Coronary Syndrome" (1 trials), "Acute Myelogenous Leukemia" (1 trials) and "Aggressive Non-Hodgkin Lymphoma" (1 trials). Many other conditions were trialed in "Hopital de Jolimont" in a lesser frequency.

Most popular intervention types in "Hopital de Jolimont" are "Drug" (19 trials), "Biological" (2 trials), "Other" (2 trials), "Procedure" (2 trials) and "Device" (1 trials). Other intervention types were less common.

The name of intervention was led by "Abemaciclib" (2 trials), "Placebo" (2 trials), "ACH-0141625 (Sovaprevir)" (1 trials), "AMG 420" (1 trials) and "ASTX727 LD" (1 trials). Other intervention names were less common.

The vast majority of trials in "Hopital de Jolimont" are 19 trials for "All" genders, 2 trials for "Female" genders and 2 trials for "Male" genders.

Currently, there are NaN active trials in "Hopital de Jolimont". undefined are not yet recruiting, 5 are recruiting, 4 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 9 completed trials in Hopital de Jolimont, undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in Hopital de Jolimont, 3 "Phase 1" clinical trials were conducted, 8 "Phase 2" clinical trials and 8 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 2 trials that are defined as “Not Applicable".